Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Employer
-
Field
-
emblem of the European Union, in compliance with the Communication Rules of Portugal 2030. VII - Selection Methods: Evaluation of the academic record (AR) VII.I - AR - In the evaluation of the academic
-
mentioned, through the Innovation Investments Strand 1 (I3-2023-INV1) program, reference number 101161143. VII - Selection Methods: Evaluation of the academic record (AR) VII.I - AR - In the evaluation
-
: Evaluation of the academic record (AR) VII.I - AR - In the evaluation of the academic record, the candidates' academic performance will be assessed according to the following weights and criteria: - Criterion
-
compliance with the Communication Rules of Portugal 2030. VII - Selection Methods: Evaluation of the academic record (AR) and Interview (I) VII.I - AR - In the evaluation of the academic record, the candidates
-
) of Portugal 2030. VII - Selection Methods: Evaluation of the academic record (AR) and/or Interview (I) VII.I - AR - In the evaluation of the academic record, the candidates' academic performance will be
-
of research results funded under the RBI must comply with the applicable open access regulations for data, publications, and other research output. VII - Selection Methods: Evaluation of the academic record (AR
-
- Selection Methods: Evaluation of the academic record (AR) and Interview (I) VII.I - AR - In the evaluation of the academic record, the candidates' academic performance will be assessed according
-
2030. VII - Selection Methods: Evaluation of the academic record (AR) and Interview (I) VII.I - AR - In the evaluation of the academic record, the candidates' academic performance will be assessed
-
the Programa Temático Inovação e Transição Digital (COMPETE 2030) of Portugal 2030. VII - Selection Methods: Evaluation of the academic record (AR) and Interview (I) VII.I - AR - In the evaluation
-
in the AR-DMRI Department of Diabetes Immunology. The research is highly translational and primarily focused on human type 1 diabetes. The major ongoing projects are investigating miRNA biomarkers